Table 2.
The summary of studies included into meta-analysis
| Author | Year | Location | Enrolment period | ACS type | Number of patients | Treatment | Men % | BMI category | Follow up (months) | Prevalence (%) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Low BMI | Normal BMI | Overweight | Obesity | Severe obesity | ||||||||||
| Hoit [17] | 1987 | USA | 1979–1983 | AMI | 1,760 | M | 75.4 | I | IH + 12 | – | 37.4 | 50.2 | 12.4 | – |
| Lopez-Jimenez [18] | 2004 | USA | 1979–1998 | AMI | 2,263 | M P T | 57.7 | G | 68.4 | – | 36.0 | 40.0 | 24.0 | – |
| Rana [19] | 2004 | USA | 1989–1994 | AMI | 1,898 | NA | 69.4 | A | 45.6 | – | 32 | 44 | 17 | 7 |
| Eisenstein [20] | 2005 | International | 1997–1999 | ACS | 15,071 | M P T C | 72.7 | E | 12 | – | 27.0 | 44.5 | 20.4 | 8.1 |
| Kragelund [21] | 2005 | Denmark | 1990–1992 | AMI | 6,168 | M T | 67.4 | M | 96 | 2.6 | 42.2 | 42.3 | 12.9 | – |
| Diercks [22] | 2006 | USA | 2001–2003 | UA/NSTEMI | 80,845 | M P C | 60.4 | D | IH | 2.9 | 26.6 | 35.9 | 20.8 | 18.8 |
| Goldberg [23] | 2006 | USA | 1997, 1999, 2001, 2003 | AMI | 3,513 | P C | 57.2 | F | IH | 7.0* | 38.5 | 29.1 | 15.5 | 9.9 |
| Iakobishvili [24] | 2006 | Israel | 2002–2003 | STEMI | 164 | P | 75.6 | J | 1.0 | – | 36.0 | 42.1 | 21.9 | – |
| Nikolsky [25] | 2006 | International | 1997–1999 | AMI | 2,035 | P | 73.1 | G | 12 | – | 27 | 45 | 28 | – |
| Wells [26] | 2006 | USA | 2003–2004 | AMI | 284 | M P T C | 68.3 | L | IH | 6.0 | 22.2 | 34.2 1 | 22.9 | 14.8 |
| Buettner [27] | 2007 | Germany | 1996–1999 | UA/NSTEMI | 1,676 | P | 66.0 | A | 17 | 0.5* | 32.9 | 49.2 | 14.6 | 17.4* |
| Mehta [28] | 2007 | International | 1990–1997 | AMI | 2,325 | P T | 73.9 | G | IH | – | 30.2 | 44.7 | 25.1 | – |
| Lopez-Jimenez [29] | 2008 | USA | 1996–2001 | AMI | 1,676 | M P C | 55.9 | K | 29 | 3.6 | 22.8 | 37.6 | 30.2 | 5.8* |
| Mehta [30] | 2008 | Germany | 1994–2002 | STEMI | 7,630 | P T | 70.7 | G | IH | – | 29.8 | 49.3 | 20.8 | – |
| Wienbergen [31] | 2008 | Germany | 1998–2002 | STEMI | 10,534 | M P T C | 70.2 | D | IH + 14 | – | 32.3 | 43.5 | 20.2 | – |
| Aronson [32] | 2010 | Israel | 2001–2007 | AMI | 2,157 | M P | 78.7 | B | 26 | 1.2 | 28.7 | 44.2 | 20.1 | 5.8 |
| Hadi [33] | 2010 | Middle East | 2006–2007 | ACS | 7,843 | P T | 75.8 | G | IH | – | 32.8 | 40.4 | 26.7 | – |
| Mahaffey [34] | 2010 | International | 2001–2003 | UA/NSTEMI | 9,873 | M P C | 66.2 | L | 1.0 | 2.4 | 23.8 | 41.5 | 21.7 | 10.1 |
| Shechter [35] | 2010 | Israel | 2002, 2004, 2006 | ACS | 5,751 | M P C | 77.0 | E | 12 | 0.8 | 29.7 | 46.9 | 22.6 | – |
| Das [36] | 2011 | USA | 2007–2009 | STEMI | 49,329 | P T | 70.5 | D | IH | – | 23.5 | 38.7 | 22.4 | 13.8 |
| Timoteo [37] | 2011 | Portugal | 2005–2008 | STEMI | 539 | P | 77.0 | C | 12 | – | 34.9 | 46.2 | 18.9 | – |
| Bucholz [38] | 2012 | USA | 2003–2008 | AMI | 6,359 | M P C | 67.4 | A | 12 | – | 22.8 | 36.4 | 24.1 | 16.7 |
| Camprubi [39] | 2012 | Spain | 2009–2010 | ACS | 824 | P | 73.5 | C | IH | – | 27.6 | 50.6 | 21.8 | – |
| Lazzeri [40] | 2012 | Italy | 2004–2010 | STEMI | 1,268 | P | 73.2 | O | IH + 12 | 2.9 | 31.8 | 51.7 | 13.6 | – |
| Herrmann [41] | 2014 | International | 2005–2007 | STEMI | 3,579 | M P C | 76.6 | H | 36 | – | 29.5 | 64.3 | 6.2 | – |
| Witassek [42] | 2014 | Switzerland | 2006–2012 | STEMI | 6,938 | P | 77.1 | A | IH | 1.0 | 33.1 | 45.0 | 15.9 | 5.0 |
| 26 Studies | 1979–2012 | 218,532 | ||||||||||||
ACS acute coronary syndrome, AMI acute myocardial infarction, UA unstable angina, NSTEMI non-ST-elevation myocardial infarction, STEMI ST-elevation myocardial infarction, NA not applicable/not available, IH in-hospital; USA United States of America, * No mortality rates/survival analysis for this BMI subgroup (only prevalence available)
Treatment: M medical treatment, T thrombolysis, P percutaneous revascularization, C coronary artery bypass surgery (CABG)
Reported BMI categories (kg/m2): A—Underweight: <18.5; Normal: 18.5–24.9; Overweight: 25–29.9; Obese: 30–34.9; Severe obese: ≥35; B—Underweight: <18.5; Normal: 18.5–21 AND 21–23.5 (reference) AND 23.5–25; Overweight: 25–26.5 AND 26.5–28 (overweight referent) AND 28–30; Obese: 30–35; Severe obese: ≥35; C—Normal: <25; Overweight: 25–29.9; Obese: >30; D—Underweight <18.5; Normal: 18.5–24.9; Overweight: 25–29.9; Obese (class I) 30–34.9; Obese: (class II) 35–39.9; Obese: (class III) ≥40 (severe obesity = class II + III obesity); E—Underweight: <18.5; Normal: 18.5–24.9; Overweight: 25–29.9; Obese: (class I, II, III) ≥30; F—Normal: <25; Overweight: 25–29.9; Obese: 30–34.9, Severe obese: ≥35; G—Normal: <25; Overweight: 25–29.9; Obese: ≥30; H—Normal: <24.5; Overweight: 24.5–27 AND 27.1–30.1; Obese: >30.1; I—Normal: <25; Overweight: 25–34.9; Obese: >35; J—Normal: ≤25; Overweight: 25–30; Obese: >30; K—Underweight: <20; Normal: 20–24.9; Overweight: 25–29.9; Obese: 30–39.9; Morbidly obese: ≥40 (obesity = ≥30); L—Underweight: <20; Normal: 20–25; Overweight: 25–30; Obese: 30–35; Severe obese: ≥35; M—Underweight: <18.5; Normal: 18.5–24.9; Overweight: 25–29.9; Obese: >30